TriangleNCT01401530 · REGISTRY CONDITION SEARCH
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE1
- Status at capture
- COMPLETED
- Registry last update
- 2018-11-23
The purpose of this Phase 1 study is to determine the maximum tolerated dose (MTD) through observation of dose limiting toxicity (DLT), which is in advance defined, in patients with peripheral or cutaneous T-cell lymphoma.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Maximum Tolerated Dose (MTD) and Recommended Dose (RD)
Number of Participants With Non-Serious Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Denileukin Diftitox
Maximum Serum Concentration (Cmax) of Denileukin Diftitox
Time to Cmax (Tmax) of Denileukin Diftitox in Serum
Area Under the Serum Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t))
Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC(0-inf))
Terminal Phase Rate Constant (λz)
Terminal Elimination Phase Half-life (t1/2)
Volume of Distribution at Terminal Phase (Vz)
Volume of Distribution at Steady State (Vss)
Total Clearance (CL)
Recommended Dose
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- lnclusion Criteria: * Male and female patients 20 to less than 80 years of age at the time of informed consent * Patients histologically or cytologically diagnosed to have peripheral T -cell lymphoma * Patients with a history of chemotherapy (including PUVA and retinoid) that resulted in relapse, recurrence and treatment resistance (just for the administration of E7777 alone) * Patients subject to CHOP therapy and without a history of prior treatment with anthracycline or anthraquinone anticancer drugs (just for the administration of E7777 in combination with CHOP therapy) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 * No carry-over of beneficial or adverse effects of the prior treatment that may affect the safety evaluation of the investigational drug (excluding Grade 1 neuropathy and alopecia) Exclusion Criteria: * Brain metastasis with clinical symptoms which requires treatment * Serious systemic infection requiring intensive treatment * Serious complications or histories * History of hypersensitivity to protein therapeutics * Known to be positive for HIV antibody, HCV antibody, or HBs antigen * History of malignancy other than peripheral T-cell lymphoma and less than five years have elapsed since the last remission * Patients who have undergone allogeneic hematopoietic stem cell transplantation * Patients with a relapse within 6 months after autologous hematopoietic stem-cell transplantation
- healthy Volunteers
- false
- maximum Age
- 79 Years
- minimum Age
- 20 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- intervention Names
- Biological: denileukin diftitox (E7777)
- label
- E7777
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- E7777
- description
- E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
- name
- denileukin diftitox (E7777)
- type
- BIOLOGICAL
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 13
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- The MTD was defined as the maximum tolerated dose observed after the evaluation of dose limiting toxicity (DLT) in Cycle 1 with 6 participants. If it was judged that the dose was not tolerated and DLT was confirmed in only 3 participants in the lower dose cohort, 3 other participants were to be added and tolerability was evaluated with 6 participants in total. The RD was to be comprehensively determined based on the MTD and safety data. Participants not evaluable for DLT were defined as participants found to be ineligible or in whom DLT evaluation was impossible due to premature termination for reasons other than toxicities in the judgement of the Sponsor, among those who had received at least one dose of the investigational drug after enrollment.
- measure
- Maximum Tolerated Dose (MTD) and Recommended Dose (RD)
- time Frame
- For each dose, first dose of study drug (Cycle 1 Day 1) to end of Cycle 1 (Day 21) (1 cycle = 3 weeks)
- secondary Outcomes
- description
- Safety assessments consisted of monitoring and recording all AEs and SAEs; regular monitoring of hematology, blood coagulation, blood chemistry, and urinalysis values; periodic measurement of vital signs, body weight, 12-lead electrocardiograms (ECGs), Eastern Cooperative Oncology Group performance status, physical examination findings, and ophthalmological examination findings. TEAEs were defined as an AE that had an onset date, or worsening in severity from baseline (pre-treatment), on or after the first dose of study drug up to the last assessment. Treatment-related TEAEs included TEAEs that were considered by the investigator to be possibly or probably related to study drug. SAEs were defined as any untoward medical occurrence which results in death, was life-threatening, required hospitalization or prolonged hospitalization, resulted in persistent or significant disability/incapacity, or caused a congenital anomaly/birth defect.
- measure
- Number of Participants With Non-Serious Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Denileukin Diftitox
- time Frame
- From date of first dose up to 30 days after the last dose of study treatment, up to approximately 4 years 2 months
- description
- Cmax was defined as the maximum observed concentration of denileukin diftitox following administration of study treatment on Cycle 1 Day 1 and was obtained directly from the measured serum concentration-time curves. Blood samples were collected before and 30 minutes after the start of infusion and immediately (0 minutes), 30, 60, 90, and 120 minutes after the end of infusion of denileukin diftitox. The samples were analyzed for the amount of denileukin diftitox in the serum using a validated ligand-binding assay with a lower limit of quantitation (LLOQ) of 30 nanograms per milliliter (ng/mL). Serum pharmacokinetic (PK) data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of Cmax, which was then summarized as the median and full range for all participants and expressed as ng/mL.
- measure
- Maximum Serum Concentration (Cmax) of Denileukin Diftitox
- time Frame
- Cycle 1 (Day 1)
- description
- Blood samples were collected before and 30 minutes after the start of infusion and immediately (0 minutes), 30, 60, 90, and 120 minutes after the end of infusion of denileukin diftitox. The samples were analyzed for the amount of denileukin diftitox in the serum using a validated ligand-binding assay with a LLOQ of 30 ng/mL. Serum PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of Tmax, which was then summarized as the median and full range for all participants and expressed in minutes.
- measure
- Time to Cmax (Tmax) of Denileukin Diftitox in Serum
- time Frame
- Cycle 1 (Day 1)
- description
- Blood samples were collected before and 30 minutes after the start of infusion and immediately (0 minutes), 30, 60, 90, and 120 minutes after the end of infusion of denileukin diftitox. The samples were analyzed for the amount of denileukin diftitox in the serum using a validated ligand-binding assay with a LLOQ of 30 ng/mL. Serum PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of AUC(0-t), which was then summarized as the median and full range for all participants and expressed as nanograms\*minutes per milliliter (ng\*min/mL).
- measure
- Area Under the Serum Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t))
- time Frame
- Cycle 1 (Day 1)
- description
- Blood samples were collected before and 30 minutes after the start of infusion and immediately (0 minutes), 30, 60, 90, and 120 minutes after the end of infusion of denileukin diftitox. The samples were analyzed for the amount of denileukin diftitox in the serum using a validated ligand-binding assay with a LLOQ of 30 ng/mL. Serum PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of AUC(0-inf), which was then summarized as the median and full range for all participants and expressed as ng\*min/mL.
- measure
- Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC(0-inf))
- time Frame
- Cycle 1 (Day 1)
- description
- Blood samples were collected before and 30 minutes after the start of infusion and immediately (0 minutes), 30, 60, 90, and 120 minutes after the end of infusion of denileukin diftitox. The samples were analyzed for the amount of denileukin diftitox in the serum using a validated ligand-binding assay with a LLOQ of 30 ng/mL. Serum PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of λz, which was then summarized as the median and full range for all participants and expressed in 1/minutes.
- measure
- Terminal Phase Rate Constant (λz)
- time Frame
- Cycle 1 (Day 1)
- description
- Blood samples were collected before and 30 minutes after the start of infusion and immediately (0 minutes), 30, 60, 90, and 120 minutes after the end of infusion of denileukin diftitox. The samples were analyzed for the amount of denileukin diftitox in the serum using a validated ligand-binding assay with a LLOQ of 30 ng/mL. Serum PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of t1/2, which was then summarized as the median and full range for all participants and expressed in minutes.
- measure
- Terminal Elimination Phase Half-life (t1/2)
- time Frame
- Cycle 1 (Day 1)
- description
- Blood samples were collected before and 30 minutes after the start of infusion and immediately (0 minutes), 30, 60, 90, and 120 minutes after the end of infusion of denileukin diftitox. The samples were analyzed for the amount of denileukin diftitox in the serum using a validated ligand-binding assay with a LLOQ of 30 ng/mL. Serum PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of Vz, which was then summarized as the median and full range for all participants and expressed as milliliters per kilogram (mL/kg).
- measure
- Volume of Distribution at Terminal Phase (Vz)
- time Frame
- Cycle 1 (Day 1)
- description
- Blood samples were collected before and 30 minutes after the start of infusion and immediately (0 minutes), 30, 60, 90, and 120 minutes after the end of infusion of denileukin diftitox. The samples were analyzed for the amount of denileukin diftitox in the serum using a validated ligand-binding assay with a LLOQ of 30 ng/mL. Serum PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of Vss, which was then summarized as the median and full range for all participants and expressed as mL/kg.
- measure
- Volume of Distribution at Steady State (Vss)
- time Frame
- Cycle 1 (Day 1)
- description
- Blood samples were collected before and 30 minutes after the start of infusion and immediately (0 minutes), 30, 60, 90, and 120 minutes after the end of infusion of denileukin diftitox. The samples were analyzed for the amount of denileukin diftitox in the serum using a validated ligand-binding assay with a LLOQ of 30 ng/mL. SerumPK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of CL, which was then summarized as the median and full range for all participants and expressed as milliliters/minutes/kilograms (mL/min/kg).
- measure
- Total Clearance (CL)
- time Frame
- Cycle 1 (Day 1)
- description
- This endpoint was combined with primary outcome measure, MTD
- measure
- Recommended Dose
- time Frame
- For each dose, first dose of study drug (Cycle 1 Day 1) to end of Cycle 1 (Day 21) (1 cycle = 3 weeks)
Full study description
- brief Summary
- The purpose of this Phase 1 study is to determine the maximum tolerated dose (MTD) through observation of dose limiting toxicity (DLT), which is in advance defined, in patients with peripheral or cutaneous T-cell lymphoma.
Source references
- references
- citation
- Ohmachi K, Ando K, Ogura M, Uchida T, Tobinai K, Maruyama D, Namiki M, Nakanishi T. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study. Cancer Sci. 2018 Mar;109(3):794-802. doi: 10.1111/cas.13513. Epub 2018 Feb 26.
- pmid
- 29363235
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-32256de02812bd345385
- requested nct id
- NCT01401530
- primary nct id
- NCT01401530
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
- payload sha256
- 9732bb7bed95a7dd8da3923e3fe3335151170fe18c24f637943ed1ea3dd1b07d
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-32256de02812bd345385
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT01401530
- occurrences
- context exact
- NCT01401530
- end
- 11
- exact text
- NCT01401530
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Peripheral T-Cell Non-Hodgkin Lymphoma
- query disease state id
- ds-peripheral-t-cell-non-hodgkin-lymphoma
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
- source file sha256
- e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
- source json pointer
- /studies/15/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 188387af5961c5c92de82049da3a458daceed377090126c76deb858e0e1db9f2
Preserved source evidence · Not medical advice